Ignite Creation Date:
2024-05-06 @ 1:10 AM
Last Modification Date:
2024-10-26 @ 10:59 AM
Study NCT ID:
NCT01740557
Status:
COMPLETED
Last Update Posted:
2023-08-31
First Post:
2012-11-30
Brief Title:
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With T -Cells Transduced With CXCR2 and NGFR Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase III trial studies how well genetically modified therapeutic autologous lymphocytes patients own white blood cells followed by aldesleukin work in treating patients with stage III melanoma or melanoma that has spread to other places in the body metastatic Placing chemokine C-X-C motif receptor 2 CXCR2 and nerve growth factor receptor NGFR into lymphocytes white blood cells may help the body build an immune response to kill melanoma cells Aldesleukin may enhance this effect by stimulating white blood cells to kill more melanoma cells Giving genetically modified therapeutic autologous lymphocytes together with aldesleukin may be a better treatment for melanoma
Detailed Description:
PRIMARY OBJECTIVES
I To assess the feasibility and safety of CXCR2 and NGFR transduced tumor-infiltrating lymphocytes TIL for treating metastatic malignant melanoma
SECONDARY OBJECTIVES
I Determine whether CXCR2 transduction enhances the ability of TIL to migrate to melanoma tumors
II Determine the levels of CXCL1 and CXCL8 chemokines produced by melanoma tumors and assess whether this correlates with the tumor localization of CXCR2 transduced TIL
III Characterize the clinical response and correlate with migration of CXCR2 transduced TIL to the tumor and levels of CXCL1 and CXCL8 at the tumor site
OUTLINE
Patients receive cyclophosphamide intravenously IV over 2 hours on days -7 and -6 fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1 and CXCR2-transduced autologous TIL and NGFR-transduced autologous TIL IV over up to 4 hours on day 0 Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 up to 15 doses and 22-26 up to 15 doses
After completion of study treatment patients are followed up at weeks 6 and 12 every 3 months for a year and then annually for up to 15 years
I To assess the feasibility and safety of CXCR2 and NGFR transduced tumor-infiltrating lymphocytes TIL for treating metastatic malignant melanoma
SECONDARY OBJECTIVES
I Determine whether CXCR2 transduction enhances the ability of TIL to migrate to melanoma tumors
II Determine the levels of CXCL1 and CXCL8 chemokines produced by melanoma tumors and assess whether this correlates with the tumor localization of CXCR2 transduced TIL
III Characterize the clinical response and correlate with migration of CXCR2 transduced TIL to the tumor and levels of CXCL1 and CXCL8 at the tumor site
OUTLINE
Patients receive cyclophosphamide intravenously IV over 2 hours on days -7 and -6 fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1 and CXCR2-transduced autologous TIL and NGFR-transduced autologous TIL IV over up to 4 hours on day 0 Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 up to 15 doses and 22-26 up to 15 doses
After completion of study treatment patients are followed up at weeks 6 and 12 every 3 months for a year and then annually for up to 15 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2014-02655 | REGISTRY | None | None |
| 2009-0471 | OTHER | None | None |
| R01CA116206 | NIH | M D Anderson Cancer Center | httpsreporternihgovquickSearchR01CA116206 |